Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221214 · ClinicalTrials.gov registry record · Phase 2
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07221214 is a Phase 2 study that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 200 participants.
The verdict
NCT07221214, a Phase 2 study, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are: 1. Does semaglutide lower the average number of alcoholic beverages participants drink per week? 2. Does semaglutide lower the average number of cigarettes participants smoke per day? 3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco? Researchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week. Participants will: 1. Take semaglutide for 3 months 2. Visit the research clinic 3 times for checkups and tests 3. Provide blood samples, stool samples, and saliva samples for tests.
Interventions
- DRUG Placebo
- DRUG Semaglutide (Rybelsus®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221214
The ClinicalTrials.gov registry entry for NCT07221214 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07221214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221214 about?
NCT07221214 is a clinical study titled "GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV". The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are: 1. Does semaglutide lower the average number of alcoholic beverages participants drink per week? 2. Does semaglutide lower the a...
What is the current status of trial NCT07221214?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-04-17. Estimated completion is 2030-01-31.
What interventions are being tested in trial NCT07221214?
The interventions under investigation include: Placebo (DRUG), Semaglutide (Rybelsus®) (DRUG).
Who is sponsoring clinical trial NCT07221214?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.